Evidence map›Paper›PMID 38113462›Full record

ArticleBlood advances2024

Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions.

Sonali J Bracken, Amy N Suthers, Rachel A DiCioccio, Hsuan Su, Sarah Anand, Jonathan C Poe, Wei Jia, Jonathan Visentin, Fahmin Basher, Collin Z Jordan and 9 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Symbiosis with and mimicry of corals were facilitated by immune gene loss and body remodeling in the pygmy seahorse.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Sonali J BrackenDivision of Rheumatology and Immunology, Department of Medicine, Duke University Medical Center, Durham, NC.ORCID 0000-0003-1814-4099
Amy N SuthersDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Rachel A DiCioccioDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Hsuan SuDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Sarah AnandDivision of Hematology and Medical Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI.
Jonathan C PoeDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Wei JiaDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.ORCID 0000-0002-3084-5288
Jonathan VisentinDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Fahmin BasherDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Collin Z JordanDivision of Nephrology, Department of Medicine, Duke University Medical Center, Durham NC.ORCID 0009-0008-7027-7319
William C McManigleDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham NC.ORCID 0000-0003-2435-2118
Zhiguo LiDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham NC.
Frances T HakimExperimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD.
Steven Z PavleticExperimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD.
Nazmim S BhuiyaExperimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD.
Vincent T HoDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Mitchell E HorwitzDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Nelson J ChaoDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.ORCID 0000-0001-6725-7220
Stefanie SarantopoulosDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Duke Medical Center · USDuke University · USNational Cancer Institute · USCentre National de la Recherche Scientifique · FRDana-Farber Cancer Institute · USUniversity of Michigan · US

Funding

NIH Chronic GVHD Study GroupZIABC011743 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLETIC, STEVEN · 2016 to 2025
$10.2M
Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHDR01HL129061 · NHLBI · DUKE UNIVERSITY · PI Stefanie Sarantopoulos · 2015 to 2026
$7.7M
Duke Program of Training in Pulmonary ReSearch to Promote, Engage and Retain Academic Researchers (PROSPER)T32HL160494 · NHLBI · DUKE UNIVERSITY · PI Jennifer L. Ingram, DAVID MARTIN MURDOCH · 2022 to 2026
$2.6M
MULTIVALENT SALMONELLA TYPHI BASED MALARIA VACCINESR01AI040297 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 1997 to 2004
$1.8M
Children's National Stimulating Access to Research in Residency (CNStARR) Program (NIAID)R38AI140298 · NIAID · CHILDREN'S RESEARCH INSTITUTE · PI FREISHTAT, ROBERT J, TEACH, STEPHEN JOHN · 2018 to 2021
$763k
NHLBI NIH HHS R01 HL129061NHLBI NIH HHS T32 HL160494NIAID NIH HHS R01 AI040297NIAID NIH HHS R38 AI140298
6 · The paper itself

Abstract

abstractChronic graft-versus-host disease (cGVHD) is a debilitating, autoimmune-like syndrome that can occur after allogeneic hematopoietic stem cell transplantation. Constitutively activated B cells contribute to ongoing alloreactivity and autoreactivity in patients with cGVHD. Excessive tissue damage that occurs after transplantation exposes B cells to nucleic acids in the extracellular environment. Recognition of endogenous nucleic acids within B cells can promote pathogenic B-cell activation. Therefore, we hypothesized that cGVHD B cells aberrantly signal through RNA and DNA sensors such as Toll-like receptor 7 (TLR7) and TLR9. We found that B cells from patients and mice with cGVHD had higher expression of TLR7 than non-cGVHD B cells. Using ex vivo assays, we found that B cells from patients with cGVHD also demonstrated increased interleukin-6 production after TLR7 stimulation with R848. Low-dose B-cell receptor (BCR) stimulation augmented B-cell responses to TLR7 activation. TLR7 hyperresponsiveness in cGVHD B cells correlated with increased expression and activation of the downstream transcription factor interferon regulatory factor 5. Because RNA-containing immune complexes can activate B cells through TLR7, we used a protein microarray to identify RNA-containing antigen targets of potential pathological relevance in cGVHD. We found that many of the unique targets of active cGVHD immunoglobulin G (IgG) were nucleic acid-binding proteins. This unbiased assay identified the autoantigen and known cGVHD target Ro-52, and we found that RNA was required for IgG binding to Ro-52. Herein, we find that BCR-activated B cells have aberrant TLR7 signaling responses that promote potential effector responses in cGVHD.

Indexed as

Bronchiolitis Obliterans SyndromeNucleic AcidsAnimalsHumansImmunoglobulin GMiceReceptors, Antigen, B-CellRNAToll-Like Receptor 7Immunoglobulin GNucleic AcidsReceptors, Antigen, B-CellRNATLR7 protein, humanToll-Like Receptor 7

Identifiers

PMID38113462
PMCPMC10839617
OpenAlexW4389942848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.